AllianceBernstein’s Prime Medicine PRME Stock Holding History

AllianceBernstein’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$425K	Buy	122,460 +13,770	+13%	+$52.4K	﹤0.01%	2718
2025 Q4	$377K	Hold	108,690	–	–	﹤0.01%	2802
2025 Q3	$602K	Sell	108,690 -58,730	-35%	-$239K	﹤0.01%	2584
2025 Q2	$414K	Buy	167,420 +91,420	+120%	+$141K	﹤0.01%	2751
2025 Q1	$151K	Hold	76,000	–	–	﹤0.01%	2993
2024 Q4	$222K	Hold	76,000	–	–	﹤0.01%	2999
2024 Q3	$294K	Buy	76,000 +5,810	+8%	+$26.9K	﹤0.01%	2927
2024 Q2	$361K	Buy	70,190 +32,240	+85%	+$195K	﹤0.01%	2838
2024 Q1	$266K	Buy	37,950 +590	+2%	+$4.47K	﹤0.01%	2845
2023 Q4	$331K	Buy	37,360 +5,520	+17%	+$42.5K	﹤0.01%	2799
2023 Q3	$304K	Buy	31,840 +5,300	+20%	+$68.8K	﹤0.01%	2801
2023 Q2	$389K	Buy	+26,540	New	+$371K	﹤0.01%	2761

Other funds holding PRME

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

AllianceBernstein's PRME Position: Q1 2026 in Review

AllianceBernstein increased its Prime Medicine (PRME) stake by 13% in Q1 2026, buying an estimated $52.4K and bringing the position to 122,460 shares worth $425K. The position accounts for ﹤0.01% of the portfolio, ranked #2718.

AllianceBernstein first reported a position in PRME in Q2 2023 and has held it in 12 quarters since. The position peaked at $602K in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

AllianceBernstein held 122,460 shares of Prime Medicine worth $425K as of Q1 2026.
AllianceBernstein bought 13,770 Prime Medicine shares in Q1 2026, an estimated $52.4K.
Prime Medicine made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2718 holding.
AllianceBernstein first reported a position in Prime Medicine in Q2 2023 and has held it in 12 quarters since.
AllianceBernstein's Prime Medicine position peaked at $602K in Q3 2025.
192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.